Is CUR a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,652 people get CUR articles and Market Currents by email alert.

Get email alerts on CUR »

HEADLINES:

Neuralstem: Update On Phase I Trial Of Neural Stem Cells In ALS Is Encouraging
Smith On Stocks • Tue, May 21 • 8 Comments
A Focus On Stem-Cell Therapy And Regenerative Medicine For 2013
A John Hodge • Mon, May 20 • 4 Comments
Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania

PR Newswire (Mon, 9:15AM)
SmithOnStocks Opines On Stocks: May 19th Edition
Smith On Stocks • Sun, May 19 • 12 Comments
Smaller Companies With Potential For Big Returns
Craig Keolanui • Thu, May 16 • 4 Comments
Neuralstem: Update On ALS Trial Could Be A Catalyst For The Stock
Smith On Stocks • Thu, May 16 • 2 Comments
Neuralstem CEO, Richard Garr, To Present At Annual World Stem Cells And Regenerative Medicine Congress In London

PR Newswire (Thu, 9:15AM)
Neuralstem Rounding Second With Phase II ALS Trial
Ryan's View • Thu, May 16 • 3 Comments
Neuralstem Principal Investigator, Dr. Eva Feldman, Presents Phase I ALS Trial Data At The Romanian Neurological Society Congress

PR Newswire (May 13, 2013)
SmithOnStocks Opines On Recent Biotech News
Smith On Stocks • Mon, May 13 • 8 Comments
Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update

PR Newswire (May 10, 2013)
Neuralstem ALS Trial Investigator And Patient On Sirius XM

PR Newswire (May 8, 2013)
Neuralstem: Anticipating More Efficacy Data From ALS Trial And Update On New Clinical Trials
Smith On Stocks • Tue, May 7 • 9 Comments
StemCells Inc: CEO Martin McGlynn Is Building A Blockbuster Company
BlackbirdAnalytics • Thu, May 2 • 13 Comments
Stem Cells: Invest At Your Own Peril
EnhydrisPECorp • Wed, May 1 • 35 Comments
Neuralstem ALS Trial Data Presented At The American Association Of Neurological Surgeons Annual Meeting

PR Newswire (Apr 29, 2013)
Regenerative Medicine's Time Has Come
Stock Investor • Sun, Apr 28 • 13 Comments
Neuralstem And The National Football League Alumni Association Announce Initiative On Brain Injury Treatment

PR Newswire (Apr 24, 2013)
FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder

PR Newswire (Apr 22, 2013)
Neuralstem CEO, Richard Garr, To Participate In Traumatic Brain Injury Panel At BIO International Convention

PR Newswire (Apr 18, 2013)

To learn more about Seeking Alpha Pro, click here.

Neuralstem: Update On Phase I Trial Of Neural Stem Cells In ALS Is Encouraging
Smith On Stocks • Tue, May 21 • 8 Comments
Neuralstem: Update On ALS Trial Could Be A Catalyst For The Stock
Smith On Stocks • Thu, May 16 • 2 Comments
Neuralstem Rounding Second With Phase II ALS Trial
Ryan's View • Thu, May 16 • 3 Comments
Neuralstem: Anticipating More Efficacy Data From ALS Trial And Update On New Clinical Trials
Smith On Stocks • Tue, May 7 • 9 Comments
Neuralstem Update Fails To Excite, All Eyes On Upcoming Phase II Trial
Brian L. Wilson • Thu, Mar 21 • 6 Comments
Neuralstem: A Top Regenerative Medicine Play
PropThink • Mon, Mar 18 • 7 Comments
ALS Crisis Of Conscience At FDA Spells Opportunity For Neuralstem, Brainstorm
Louis Dematteis • Thu, Mar 7 • 7 Comments
After Successful ALS Phase I, Neuralstem Branches Out
Hilltop Warrior • Tue, Mar 5 • 5 Comments
Neuralstem Shows ALS Can Be Beaten Back - Now On To Phase II
Andreas Spiro • Wed, Dec 19, 2012 • 10 Comments
Investors Chase Neuralstem On Successful Phase I Trial
Brian L. Wilson • Tue, Dec 4, 2012 • 10 Comments
Is NeuralStem The Next Sarepta?
Carl Cachia • Wed, Nov 28, 2012 • 12 Comments
Neuralstem Is Speculative, But Its Work In Stem Cell Therapy Can't Be Ignored
Smith On Stocks • Tue, Nov 6, 2012 • 14 Comments
Fish Oil Approach To Neurological Treatment: Neuralstem Vs. Forest Labs And Acorda
EricFinance • Tue, Oct 23, 2012 • 4 Comments
Will The Sanofi Pompe Paradigm Play Out With Neuralstem And Lou Gehrig's Disease?
Andreas Spiro • Fri, Oct 5, 2012 • 12 Comments
What Next For Neuralstem?
Brian L. Wilson • Tue, Oct 2, 2012 • 11 Comments
Why Neuralstem Could Provide A 10x Return
John H. Ford • Tue, Sep 11, 2012 • 28 Comments
Vivus, Arena: Don't Be Too Late To The Punch Bowl, Buy Other Stocks
Takeover Analyst • Sat, Sep 8, 2012 • 14 Comments
Neuralstem Loses $0.08/Share in Q2
Henry McCusker • Thu, Aug 11, 2011 • 2 Comments
Neuralstem Sponsors Stem Cell Research in Taiwan
ChinaBio Today • Tue, Jul 14, 2009

A Focus On Stem-Cell Therapy And Regenerative Medicine For 2013
A John Hodge • Mon, May 20 • 4 Comments
SmithOnStocks Opines On Stocks: May 19th Edition
Smith On Stocks • Sun, May 19 • 12 Comments
Smaller Companies With Potential For Big Returns
Craig Keolanui • Thu, May 16 • 4 Comments
SmithOnStocks Opines On Recent Biotech News
Smith On Stocks • Mon, May 13 • 8 Comments
StemCells Inc: CEO Martin McGlynn Is Building A Blockbuster Company
BlackbirdAnalytics • Thu, May 2 • 13 Comments
Stem Cells: Invest At Your Own Peril
EnhydrisPECorp • Wed, May 1 • 35 Comments
Regenerative Medicine's Time Has Come
Stock Investor • Sun, Apr 28 • 13 Comments
2 Biotech Stocks Announcing Key Early Stage Clinical Developments
Heather Ingrassia • Wed, Apr 17 • 1 Comment
Investing In The Stem Cell Sector: An Overview
EnhydrisPECorp • Wed, Apr 17 • 25 Comments
The Vatican / NeoStem Partnership Looks To Create Interest And Advance Cell Therapy
Brian Nichols • Wed, Apr 10 • 28 Comments
Updating A Speculative Idea And Sharing A New One
Alan Brochstein • Mon, Apr 1 • 9 Comments
Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy
Bioassociate Consulting • Thu, Mar 28 • 5 Comments
Buy Hercules Tech Growth Capital Instead Of OCZ Tech
Stone Fox Capital • Wed, Mar 27 • 12 Comments
The Future Of Medicine: A Look At 5 Stem Cell Companies
Craig Keolanui • Fri, Mar 22 • 4 Comments
Valuing Amarantus - Where Financial Reality Meets Scientific Hope
Jason Napodano • Mon, Mar 11 • 12 Comments
Regenerative Medicine: Some Realism Please
Douglas W. House • Fri, Feb 22 • 29 Comments
Athersys: The Coming Year Will Define MultiStem, Its Adult Stem Cell Product
Smith On Stocks • Fri, Feb 8 • 19 Comments
Insight On Advanced Cell Technology: An Interview With Gary Rabin, Chairman And CEO
Michael J. Ray • Fri, Feb 8 • 26 Comments
3 Regenerative Medicine Companies That Could Deliver In 2013
A John Hodge • Tue, Jan 22 • 18 Comments
Stem Cell Stocks To Consider: Aastrom, Athersys, StemCells And Neuralstem
BuySellShort • Wed, Jan 16 • 6 Comments

Neuralstem: Wall Street Analyst Forum Presentation Transcript
Tue, May 22, 2007 • 3 Comments

Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania

PR Newswire (Mon, 9:15AM)
Neuralstem CEO, Richard Garr, To Present At Annual World Stem Cells And Regenerative Medicine Congress In London

PR Newswire (Thu, 9:15AM)
Neuralstem Principal Investigator, Dr. Eva Feldman, Presents Phase I ALS Trial Data At The Romanian Neurological Society Congress

PR Newswire (May 13, 2013)
Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update

PR Newswire (May 10, 2013)
Neuralstem ALS Trial Investigator And Patient On Sirius XM

PR Newswire (May 8, 2013)
Neuralstem ALS Trial Data Presented At The American Association Of Neurological Surgeons Annual Meeting

PR Newswire (Apr 29, 2013)
Neuralstem And The National Football League Alumni Association Announce Initiative On Brain Injury Treatment

PR Newswire (Apr 24, 2013)
FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder

PR Newswire (Apr 22, 2013)
Neuralstem CEO, Richard Garr, To Participate In Traumatic Brain Injury Panel At BIO International Convention

PR Newswire (Apr 18, 2013)
Neuralstem Receives FDA Approval To Commence Phase II Stem Cell Trial In Amytrophic Lateral Sclerosis

PR Newswire (Apr 17, 2013)
Neuralstem Receives Notice Of Allowance Of Patent Covering Use Of Stem Cells To Treat Amyotrophic Lateral Sclerosis

PR Newswire (Apr 5, 2013)
Neuralstem Secures $8 Million In Debt Financing From Hercules

PR Newswire (Mar 25, 2013)
Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update

PR Newswire (Mar 15, 2013)
Neuralstem CEO, Richard Garr, Named To "Top 50 Global Stem Cell Influencers"

PR Newswire (Mar 14, 2013)
Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center

PR Newswire (Feb 20, 2013)
Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013

PR Newswire (Feb 7, 2013)
Neuralstem Receives FDA Approval To Commence Spinal Cord Injury Trial

PR Newswire (Jan 14, 2013)
Neuralstem President and CEO to Present 2013 Trials Overview at 2013 Biotech Showcase

PR Newswire (Jan 4, 2013)
Neuralstem Investigator Presents New ALS NSI-566 Data at International Symposium on ALS/MND

PR Newswire (Dec 10, 2012)
Neuralstem Reports Third Quarter Financial Results And Provides Update On Clinical Programs And Business Highlights

PR Newswire (Nov 9, 2012)

CUR vs. ETF Alternatives

Company Description

Currently, there's no company description for CUR.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 10:46 AM Shares of stem cell research firms are rallying today on the back of an announcement today by the Oregon Health and Science University that they've successfully reproduced human stem cells by cloning. Cloning stem cells in this fashion could lead to cell therapies using a patient’s own cells and thereby avoid the problems of immune suppression: StemCells (STEM +2.2%), NeuralStem (CUR +2.1%), NeoStem (NBS +2.2%). Comment! [Healthcare, On the Move]
Friday, May 10, 4:31 PM Neuralstem (CUR): Q1 EPS of -$0.05 in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, April 22, 9:46 AM Neuralstem (CUR +2.7%-) ticks higher at the open after the FDA gives the go ahead to begin dosing its third and final cohort of patients in its ongoing Phase Ib safety trials of NSI-189, a treatment for major depressive disorder. Comment! [Healthcare, On the Move]
Friday, April 19, 12:31 PM Neuralstem (CUR +2.7%-) ticks higher at the open after the FDA gives the go ahead to begin dosing its third and final cohort of patients in its ongoing Phase Ib safety trials of NSI-189, a treatment for major depressive disorder.
2 Comments [Earnings, On the Move, Consumer, Global & FX]
Wednesday, April 17, 9:19 AM Neuralstem (CUR) is set to open sharply higher after saying the FDA has approved the company's request to begin a Phase II trial of NSI-566 human neural stem cells for the treatment of Lou Gehrig's disease. A Phase I study suggested the therapy interrupted the progression of the disease. Shares +11.32% Comment! [Healthcare, On the Move]
Wednesday, April 17, 9:12 AM Premarket gainers: VRML +29%. ACUR +26%. OCZ +18%. CUR +9%. ALKS +9%. ABMD +9%. ASML +6%.
Losers: EOPN -29%. INWK -25%. CXW -15%. MHR -12%. ZGNX -11%. TXT -9%. CRUS -7%. VRNG -6%. 1 Comment [On the Move]
Monday, March 25, 3:43 PM Neuralstem (CUR -2.7%) slips after earlier saying it's secured $8M in debt financing from Hercules Technology to fund the company's capital budget through late 2014. The company has multiple cell therapy clinical trials planned this year, including upcoming Phase 2 ALS trials in the U.S. Comment! [Healthcare, On the Move]
Monday, January 14, 9:41 AM Neuralstem (CUR) jumps 12.1% after it receives approval from the FDA to start a Phase I safety trial of its lead cell therapy treatment, NSI-566, in eight patients who have become complete paralyzed due to spinal-cord injuries. Neuralstem has already conducted 18 successful surgeries using the same cells and surgical device that it will use in the new trial. (PR) Comment! [On the Move, Healthcare]
Monday, January 14, 9:09 AM Premarket gainers: AZK +29%. CUR +14%. AVNW +13%. HWD +11%. VRNT +10%. NICE +8%. FIO +6%. FRAN +6%. DNDN +5%. ALU +6%.
Losers: NTE -11%. CRUS -6%. Comment! [On the Move]
Friday, December 7, 2012, 12:50 PM Midday top 10 gainers: CBMX +184%. GTIM +48%. LTBR +18%. DLGC +17%. RECV +16%. UNXL +15%. PAMT +15%. TELK +14%. JKS +14%. XPLR +11%.
Midday top 10 Losers: TOPS -23%. AMRN -19%. KUTV -15%. VTSS -13%. MBLX -11%. CHLN -11%. CHTP -9%. RGC -8%. CUR -8%. AACC -8%. Comment! [On the Move]
Tuesday, December 4, 2012, 12:45 PM Midday top 10 gainers: ALDA +54%. SINO +29%. CYCC +17%. LTBR +12%. CORT +12%. SAB +11%. EDMC +10%. CPGI +11%. PRIS +10%. ACLS +10%.
Midday top 10 Losers: UEPS -56%. GERN -24%. EXA -22%. CUR -20%. SSN -19%. PPHM -16%. IQNT -18%. PBY -14%. GURE -12%. LEDS -12%. 3 Comments [On the Move]
Monday, December 3, 2012, 2:28 PM Neuralstem (CUR +7.2%) spikes, possibly related to a Crain's article reporting "amazing results" in a patient who received 500K stem cells derived by CUR. 1 Comment [On the Move, Healthcare]
Tuesday, November 27, 2012, 12:45 PM Midday top 10 gainers: ACAD +141%. CPSL +30%. IMMR +30%. RAH +27%. TSPT +12%. BWEN +12%. CUR +12%. FOLD +10%. FONR +10%. CDTI +10%. Midday top 10 Losers: STV -11%. MMR -9%. THO -11%. RECV -10%. CBAK -9%. BLIN -12%. ENMD -8%. RGDX -8%. ARCI -8%. BV -8%. Comment!
Wednesday, October 17, 2012, 10:35 AM Neuralstem (CUR +0.9%) starts testing the safety of its NSI-189 treatment for Major Depressive Disorder on a second set of patients after receiving FDA approval to do so. "There were no surprises" in the first cohort of patients in the Phase Ib study, the company says. (PR) Comment! [Healthcare]
Tuesday, October 16, 2012, 9:10 AM Premarket gainers: NOOF +54%. THLD +12%. MUR +8%. AEGR +7%. JOEZ +7%. CUR +7%. DPZ +6%.
Losers: RATE -26%. ISIS -20%. CLWR -19%. CMRE -10%. WAC -5%. GWW -5%. 1 Comment [On the Move]
Monday, October 15, 2012, 3:16 PM Neuralstem (CUR +7.3%) pops after releasing positive results for its NSI-566 study, a spinal cord-derived neural stem cell line tested in a rat model of ischemic stroke. The data showed significant improvement in both motor and neurological tests, with the rats treated with the highest dose showing the most significant improvement in both categories. 3 Comments [Healthcare, On the Move]

Joseph P. Porter
Market seems to be opening on a downer - $CUR, $DCIX, $KKR, $NTI, $ONTY, $PFE, $RNO all down, if only marginally in some cases. Must go up!
May 1, 9:55 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joseph P. Porter
$CUR had good news last week, and gained some but fell back. Will it continue on the upside this week?
Apr 28, 6:11 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joseph P. Porter
The mixed week in earnings takes its toll today: $CUR, $DCIX, $KKR, $ONTY, $PFE and $RNO all down, even though many gave good news this week
Apr 26, 12:22 PM
Reply (5)

• !Report Abuse
View all 5 replies
neobliviscar: Ja mata. Let me frame it then. The stock is only up +10% this week. It was up +11%, except for that Charlie Sheen Violent Torpedo of Truth.
Apr 26, 1:34 PM
• !Report Abuse
Joseph P. Porter: P.S. I'm long DCIX.
Apr 26, 2:16 PM
• !Report Abuse
Add a reply...

140 characters

ggoldsmith
$CUR: Any thoughts about the value of the new NFL sponsorship of CUR's stock. Will this bring any money to them?
Apr 25, 12:06 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joseph P. Porter
$CUR and $ONTY up yesterday - $ONTY surprisingly strong lately.
Apr 23, 12:06 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joseph P. Porter
$CUR is up on getting the go-ahead for Phase II trials for ALS.
Apr 17, 5:00 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joseph P. Porter
$ONTY up $0.20+. Must be some kind of record. $CUR up, should be reporting on some of its research soon.
Apr 9, 3:08 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

richardod
started biotech 12M- $GALE should be good but moving slowly $EYCT (UP60%) $PSTI now back buying ATHX do not see more winners - $CUR? ++?
Mar 28, 5:48 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Robbster
Biotech holds include $ARQL, $CUR, $GALE, $IMUC, $NBS, $PSTI, $ STEM, $NLNK. Questioning ARQL, NLNK, but holding for now...
Mar 12, 10:21 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Robbster
So, for those following, my total development biotech portfolio as of today: $ARQL, $CUR, $DNDN, $GALE, $IMUC, $NBS, $NLNK, $PSTI, $STEM.
Jan 3, 8:24 PM
Reply (1)

• !Report Abuse
View all 1 replies
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
Jan 5, 3:09 PM
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Joseph P. Porter
The mixed week in earnings takes its toll today: $CUR, $DCIX, $KKR, $ONTY, $PFE and $RNO all down, even though many gave good news this week
Apr 26, 12:22 PM
Reply (5)

• !Report Abuse
View all 5 replies
neobliviscar: Ja mata. Let me frame it then. The stock is only up +10% this week. It was up +11%, except for that Charlie Sheen Violent Torpedo of Truth.
Apr 26, 1:34 PM
• !Report Abuse
Joseph P. Porter: P.S. I'm long DCIX.
Apr 26, 2:16 PM
• !Report Abuse
Add a reply...

140 characters

Robbster
So, for those following, my total development biotech portfolio as of today: $ARQL, $CUR, $DNDN, $GALE, $IMUC, $NBS, $NLNK, $PSTI, $STEM.
Jan 3, 8:24 PM
Reply (1)

• !Report Abuse
View all 1 replies
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
Jan 5, 3:09 PM
• !Report Abuse
Add a reply...

140 characters

skywola
I think that CUR will be at $5 a share before long . . . Stem cells stocks will be the Apples and Microsofts of the future.
9/17/12
Reply (5)

• !Report Abuse
View all 5 replies
skywola: I have not seen any info like that, but I have not dug very deep either, so it could be out there.
9/21/12
• !Report Abuse
jb1201: It will be released on Monday October 8th around 5:30.
10/4/12
• !Report Abuse
Add a reply...

140 characters

Joseph P. Porter
So much for that. AGNC down $.29, all REITs down. My bioPharms both up (PFE & CUR). Too bad BioPharms don't pay big divs.
9/25/12
Reply (2)

• !Report Abuse
View all 2 replies
wallstreetpro2: yep all my reit went down to NYMT ARR MTGE AGNC usually in bad tape they been going up
9/25/12
• !Report Abuse
Joseph P. Porter: yeah - AGNC, TWO, ARR, CXS AND MFA usually go up nicely on bad market days. Oh well, there's always the chance of a flash crash.
9/25/12
• !Report Abuse
Add a reply...

140 characters

Joseph P. Porter
CUR drops price to $1 on secondary release. A bit more than expected. Is it a big mistake? ($1.25 would have been better.)
9/14/12
Reply (1)

• !Report Abuse
View all 1 replies
Ocean Man: Yeah, that seemed like an unnecessarily large discount.
9/14/12
• !Report Abuse
Add a reply...

140 characters

johnjail
Increased stake in ATRS, AMPE, ARRY. I'm thinking about for a speculative position in CUR at current 0.75$ is mouthwatering...
8/10/12
Reply (2)

• !Report Abuse
View all 2 replies
joe kelly: DRRX man! Nobody's talking about it. They will.
8/10/12
• !Report Abuse
johnjail: nice pipeline and nice last quarter :) but I didn't find the cash they have and the burn rate. at that price seems to be interesting
8/11/12
• !Report Abuse
Add a reply...

140 characters

CUR Neuralstem, Inc.

CUR

Neuralstem, Inc.